AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06280287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FAPI PET
Description: 68Ga-FAPI PET/MR with high-resolution cardiovascular magnetic resonance vessel wall imaging for patients with carotid stenosis; 18FAl-FAPI PET/CT for patients with coronary artery disease
Study NCT06561230 — intervention group
Intervention type: OTHER
Intervention: Chart review
Description: Patients eligible for prescreening will be identified using structured criteria (e.g., anyone with an appointment in the upcoming 2 months with a relevant provider). All individual charts will be de-identified. De-identified EHRs will then be transferred to Mendel's secure data abstraction platform, where trial eligibility criteria will be abstracted. Patients will be rank-ordered by number of eligibility criteria met, with patients meeting the most eligibility criteria at the top of the queue. The study team will then review eligibility criteria and flag eligible patients.
Study NCT05711888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic Recognition Procedure
Description: A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.
Study NCT05754684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cell
Description: Natural killer cells isolated from HLA-haploidentical relative donor
Study NCT05754684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab beta
Description: Dinutuximab beta iv for 5 days
Study NCT05754684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 sc alternate day for 6 doses
Study NCT05754684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: Granulocyte-macrophage colony-stimulating factor sc daily till ANC >2,000/mm3
Study NCT05754684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone po three time daily
Study NCT05754684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Naxitamab iv for 4 days (as alternative for dinutuximab)
Study NCT06035614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: exciplex
Description: exciplex, excimer lamp 308nm produced by clarteis
Study NCT06035614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus ointment
Description: tacrolimus monohydrate ointment 0.1% TACRUS
Study NCT04963361 — intervention group
Intervention type: OTHER
Intervention: patients were exposed to fear of movement
Description: Patients completed the questionnaires independently
Study NCT04963361 — intervention group
Intervention type: OTHER
Intervention: patients were not exposed to fear of movement
Description: Patients completed the questionnaires independently
Study NCT04714437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: F
Description: The participant will be asked to chew the latex bag naturally.
Study NCT04714437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: The participant will be asked to chew the latex bag unilaterally on the right-side.
Study NCT04714437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: L
Description: The participant will be asked to chew the latex bag unilaterally on the left-side.
Study NCT04714437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A1
Description: The participant will be asked to chew the latex bag changing the side once.
Study NCT06032052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single drug chemotherapy plus immunotherapy
Description: The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
Study NCT04874233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is active study drug
Study NCT04874233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active study drug N = 20
Study NCT04714437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A3
Description: The participant will be asked to chew the latex bag changing the side three times.
Study NCT04714437 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A5
Description: The participant will be asked to chew the latex bag changing the side five times.
Study NCT06474689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR
Description: EMDR is based on the Adaptive Information Process (AIP) model, which posits that the traumatic event experienced by a subject is stored in memory along with the disturbing emotions, perceptions, cognitions, and physical sensations that characterized that moment. All this information is stored in a dysfunctional way within neural networks and unable to connect with other networks with useful information. The information enclosed in the neural networks, not being able to be processed, continue to cause discomfort in the subject, up to the onset of pathologies such as post-traumatic stress disorder (PTSD) and other psychological disorders. The goal of EMDR is to restore the adaptive processing of information in order to achieve the adaptive resolution by creating new and more functional connections.
Study NCT06474689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT-E is based on the transdiagnostic theory for eating disorders. According to this theory, there is an overvaluation of shape, weight, eating and their control that people use to judge themselves which represents the core feature of maintaining eating disorder symptoms including binge eating. The goals of CBT-E are to increase the understanding of eating disorders, reduce weight concerns, and establish a pattern of regular eating by addressing the mechanisms that have been maintaining the eating disorder psychopathology including body image disturbances and reactions to life events and emotions. The goals of CBT-OB are to help patients to reach, accept and maintain a healthy weight loss by adopting a healthy lifestyle.
Study NCT05443425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Given PO
Study NCT05443425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study NCT05443425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Therapy
Description: Given steroid therapy
Study NCT06442540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Agents
Description: Hot pack
Study NCT06442540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: HVLA manipulation of SI joint
Study NCT06442540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises
Description: Supine abdominal draw-in Hold 8s 3s off x 2 Abdominal draw-in, with one knee drawn to the chest. Hold 8s 3s off x 2 Abdominal draw-in, with the heels sliding backward one after the other. 10 reps 3s off x 2 Abdominal draw-in, with both knees drawn to the chest. Hold 8s 3s off x 2 Supine twist 15 reps 3s off x 3 Prone bridging on elbows Hold 8s 3s off x 3 Side bridging on elbows Hold 8s 3s off x 3 Quadruped opposite arm-leg lift Hold 8s 3s off x 3 Advance to the stage 2 when the patient can hold 30 reps for an 8-sec hold.
Study NCT06442540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramusular electrotherapy
Description: Intramuscular electrotherapy/ 3 sessions per week
Study NCT06442540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue mobility
Description: Stretching and Myofacial Release of piriformis and erector spinae
Study NCT06451315 — intervention group
Intervention type: PROCEDURE
Intervention: Analyze CTscans pre-operatively by Nurea System
Description: CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by system develop by Nurea
Study NCT06451315 — intervention group
Intervention type: PROCEDURE
Intervention: Analyze CTscans pre-operatively by hospital practitioner
Description: CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by an hospital practitioner
Study NCT06014736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XJ101 for Injection
Description: XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.
Study NCT06014736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only excipients.
Study NCT04727476 — intervention group
Intervention type: DRUG
Intervention: Lisdexamfetamine
Description: Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
Study NCT04340908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: 10 mg tablet, oral, once daily, 1-year treatment, postoperation
Study NCT04340908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: matching placebo tablet, oral, once daily, 1-year treatment, postoperation
Study NCT05914025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Individuals will be provided with information about maladaptive patterns of behavior and how to correct these cycles with activity scheduling to elicit more positive emotional experiences. Participants will be provided with categories/lists of activities and a downloadable calendar after receiving the psychoeducation.
Study NCT04613882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Toric Custom Made Contact lens
Description: Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
Study NCT04613882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Toric Custom Made Contact lens
Description: Subjects will be randomized to wear soft toric custom made lenses for 30 minutes in one eye with other eye patched.
Study NCT04613882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Spherical Contact Lenses
Description: Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
Study NCT04613882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Spherical Contact Lenses
Description: Subjects will be randomized to wear soft spherical contact lenses for 30 minutes in one eye with other eye patched.
Study NCT04613882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle Correction
Description: Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
Study NCT01048983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
Study NCT04613882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle Correction
Description: Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
Study NCT06017674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular Pulsed Radiofrequency
Description: A 22-gauge 10 cm radiofrequency cannula with a 10-mm active tip was advanced to the mid-tibiofemoral joint under fluoroscopic guidance. After needle insertion, paresthesia-pain and motor stimulation tests were performed using sensory (50 Hz) and motor (2 Hz, 1 V) stimulation to confirm the absence of stimulation. Intra-articular Pulsed Radiofrequency (IAPRF) was applied at 45 V voltage for 20 ms pulse width for 360 s, followed by a 480 ms silent phase. The tissue temperature was adjusted to not exceed 42°C.
Study NCT06017674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Injection
Description: 8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.
Study NCT06380634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group- Motivational Interview
Description: Pregnant women who applied to the gynecology clinic and met the inclusion criteria were informed about the study. Those who agreed were informed about the purpose of the research. Firstly, the Informed Volunteer and Introductory Information Form was applied to the women, then the Personal Care Products Use Evaluation Form, Self-Efficacy Scale and Endocrine Disruptors Attitude Scale were applied. Then, the experimental group was informed about the motivational interviewing technique. A total of 3 interviews were held. The final test was made at the fourth meeting.
Study NCT06379113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
Study NCT06379113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: 2.5mg po qd.
Study NCT04774822 — intervention group
Intervention type: PROCEDURE
Intervention: Color Fundus Photography
Description: Stereoscopic Fundus photography
Study NCT04774822 — intervention group
Intervention type: DRUG
Intervention: Mydriatics Agent
Description: Eye dilating agent
Study NCT04774822 — intervention group
Intervention type: PROCEDURE
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Tomographic imaging of retina
Study NCT06273982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)
Description: STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.
Study NCT06273982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ARC (assisted referral to community care)
Description: ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.
Study NCT01048983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Study NCT06021951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid 180 MG Oral Tablet
Description: Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]
Study NCT06021951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet
Description: Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]
Study NCT01048983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
Study NCT05668936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide
Description: Participants will receive a subcutaneous injection of cotadutide.
Study NCT05668936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide-placebo
Description: Participants will receive a subcutaneous injection of cotadutide-placebo.
Study NCT06111196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection
Description: 100mg/4ml;single dose;intravenous injection
Study NCT06111196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: 100mg/4ml;single dose;intravenous injection
Study NCT06570343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl-Morphine
Description: Intrathecal injection of bupivacaine, fentanyl and morphine
Study NCT06570343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal injection of bupivacaine and morphine
Study NCT06086561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Anisotropy Measurement Device
Description: The study device is a non-invasive sensor that is placed on the study subject's skin overlying an existing implanted CSF shunt. It uses an integrated thermal actuator and temperature sensors to assess shunt flow.
Study NCT06648538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonix Care
Description: Phonix Care consists of a 5-month digital therapeutic program that encourages the user to engage in non-digital activities through pre-defined screen rules and off-screen challenges validated by smartphone sensors.
Study NCT06431893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtibatinase
Description: Full Target Dose of pegtibatinase BIW
Study NCT06064838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoids
Description: 1 capsule every 12h for 90 days
Study NCT06064838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavonoids
Description: 1 capsule every 12h for 90 days
Study NCT06668285 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no intervention
Description: no intervention
Study NCT06668285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental presence
Description: parental presence
Study NCT06668298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Description: The formula for postoperative analgesia pump is oliceridine 0.4mg · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
Study NCT06668298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfentanil
Description: The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
Study NCT06667102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic and Interactive Signing Instruction
Description: SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.
Study NCT06667427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve transfer techniques
Description: Participants will undergo facial nerve reconstruction using nerve transfer techniques
Study NCT06459349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exteroceptive and proprioceptive sensory stimulation training
Description: Patients in this group will receive intervention exteroceptive and proprioceptive sensory stimulation for 50 minutes per session, 03 times a week, for 06 weeks
Study NCT06459349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sensorimotor therapy group
Description: Patients will receive sensorimotor therapy for 50 minutes per session, 03 times a week, for 06 weeks
Study NCT06616675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: Anticholinergic drug therapy for OAB treatment - Darifenacin, 15mg/day
Study NCT06616675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation - Sacral nerve stimulation
Description: Neurodyn Portable TENS FES neuromuscular stimulation device in an outpatient clinic. Two self-adhesive electrodes (5x9cm) were used, positioned one in each gluteal region, below the iliac spine to apply low-frequency biphasic current with 10 Hz. Pulse duration of 0.5 milliseconds was applied for 40 minutes with continuous stimulation, 3 times a week, for 20 sessions.
Study NCT06618716 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
Description: Intravenous administration of endotoxin (0.8 ng/kg body weight)
Study NCT06618716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placcebo
Description: Placebo injection of 0.9% NaCl
Study NCT05668936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
Study NCT05668936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-placebo
Description: Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.
Study NCT06618196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LR20062
Description: DTaP-HepB-IPV-Hib vaccine
Study NCT05632536 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SACRAL ESP AND CAUDAL BLOCK
Description: Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
Study NCT06618196 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HepB-IPV-Hib vaccine
Description: Control hexavalent vaccine
Study NCT06623617 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Three-dimensional breathing training
Description: Engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. They will also be guided to log their daily training, manually inputting data such as duration and frequency. A virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.